表紙
市場調査レポート

医薬品有力企業シリーズ:生物製剤メーカー上位20社

Pharma Leader Series: Top 20 Biological Drug Manufacturers 2012-2022

発行 Visiongain Ltd 商品コード 253509
出版日 ページ情報 英文 187 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=142.08円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。
制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
医薬品有力企業シリーズ:生物製剤メーカー上位20社 Pharma Leader Series: Top 20 Biological Drug Manufacturers 2012-2022
出版日: 2012年10月09日 ページ情報: 英文 187 Pages
概要

当レポートでは、生物製剤メーカー上位20社の動向について調査分析し、市場概要・製品構成・需要・将来性、主要事業者の企業概要、主要製品、財務実績、事業戦略、将来の展望などをまとめ、概略下記の構成でお届けいたします。

第1章 エグゼクティブサマリー

第2章 世界の生物製剤市場概要

  • 生物製剤
  • 生物製剤市場
  • 生物製剤の主要クラス
  • 生物製剤市場:全体収益の予測
  • 生物製剤市場:促進因子・阻害因子
  • 生物製剤メーカー上位20社

第3章 主要生物製剤メーカー:Roche

  • 概要
  • ポートフォリオ
  • 生物製剤パイプライン
  • 促進因子・阻害因子
  • 収益予測

第4章 バイオテクノロジー・専門メーカー

  • Amgen
  • Biogen Idec
  • CSL Behring
  • Grifols
  • Allergan

第5章 主要ワクチンメーカー

  • Sanofi
  • Pfizer
  • GlaxoSmithKline
  • Merck & Co.,
  • Novartis

第6章 欧州の主要生物製剤メーカー

  • Novo Nordisk
  • Merck KGaA
  • Bayer
  • AstraZeneca

第7章 米国の主要生物製剤メーカー

  • Johnson & Johnson
  • Abbott Laboratories
  • Baxter
  • Eli Lilly
  • Bristol-Myers Squibb

図表リスト

目次

New study shows you commercial prospects for leading biopharmaceutical companies

How are companies in the biological medicines (biologics) industry performing? Visiongain's new report shows you organisations' prospects to 2022. There you find financial data, trends, opportunities and commercial potentials.

We assess 20 leading developers and producers of biological drugs and vaccines - our analyses help you see the future of the biopharma industry and market. See how sales can increase.

In our investigation you discover a biologics revenue forecast for each company, growth rates, rankings and market shares. Also, you see qualitative analyses, news, research and development (R&D) and business outlooks. You receive 113 tables and 80 charts.

Our work lets you assess the most lucrative areas of the biologicals market, especially 20 companies at the forefront of biopharmaceuticals. Their technologies hold great promise.

You can stay ahead in knowledge. The following sections highlight what you find in the report.


The leading company - you find prospects to 2022 for Roche

Roche is the first company our study analyses. See information on its products and activities in 2012, looking ahead.

You find discussions and analysis of its product portfolio:

  • Rituxan
  • Avastin
  • Herceptin
  • Lucentis
  • Pegasys and other agents.

Also you investigate Roche's R&D pipeline, its commercial challenges from 2012 and a forecast of its biologics revenue to 2022. Next, our report covers many other companies.

You see prospects for leading pharmaceutical biotechs and specialist manufacturers

Our report gives you profiles and analyses for many other companies, including biopharmaceutical specialists such as these:

  • Sanofi
  • Novo Nordisk
  • Pfizer
  • GlaxoSmithKline (GSK)
  • Merck & Co.
  • Novartis
  • Amgen
  • Biogen Idec
  • CSL Behring
  • Grifols
  • Allergan.

You examine product portfolios, breakdowns of sales, R&D pipelines and outlooks, including biologics revenue forecasts to 2022. Our study also covers vaccines. You find analyses of competition, as well as commercial drivers and restraints for those companies and others.

You discover prospects for other leading developers and manufacturers of biological drugs

Our investigation shows you prospects for other biological medicine producers, including revenue forecasts to 2022 with discussions.

See prospects for other leading European companies:

  • Merck KGaA
  • Bayer
  • AstraZeneca.

See prospects for other leading US companies:

  • Johnson & Johnson (J&J)
  • Abbott Laboratories
  • Baxter
  • Eli Lilly
  • Bristol-Myers Squibb (BMS).

This decade many opportunities will arise for large entities and specialty healthcare firms. See outlooks and revenue forecasts for the top 20 players. In our work you assess R&D and other issues influencing future results.

You investigate what affects companies and their market, seeing its revenue prospects too

Our report also analyses and discusses the overall market for biological drugs and vaccines. You see what influences the biopharma sector from 2012:

  • Competition, collaborations, technology and product licensing
  • Corporations, mergers and acquisitions (M&A deals - e.g. GSK and Human Genome Sciences in summer 2012)
  • R&D - immunotherapies, plasma agents, hormones and other proteins and recombinant molecules, including cellular therapies
  • Opportunities in treating cancers, CNS disorders, inflammatory diseases, viral infections, blood ailments, diabetes, eye diseases and other medical conditions
  • Strengths, weaknesses, opportunities and threats, including the entry of biosimilars and follow-on protein products.

There you investigate prospects for therapeutic proteins, monoclonal antibodies (mAbs), vaccines, fusion proteins and other biotechnological medicines. See what the future holds.

You also assess biological therapies by overall world market and product class (five submarkets), seeing forecasted revenues, sales shares and growth rates to 2022.

The biologics segment is growing faster than the overall world pharmaceutical market, a trend that will continue, our analyses predict. From 2012, biologic blockbusters will fill many of the top sales places. Also, most of those products will continue revenue growth.

Seven ways Pharma Leader Series: Top 20 Biological Drug Manufacturers 2012-2022 helps you

In particular, our report gives you the following knowledge on producers of biologics:

  • Profiles of 20 leading companies - discover products, recent results, sales breakdowns, strategies, competition and outlooks
  • Forecasted revenues to 2022 for the 20 leading companies - analyse predicted financial results for each company
  • Potential revenues to 2022 for the overall world market and 5 biological product submarkets - find the biopharma industry's sales prospects
  • Review of R&D pipelines - investigate developmental trends and progress
  • Investigation of competition and opportunities influencing biomedical sales
  • Discussion of what stimulates and restrains companies, the industry and the market
  • Prospects for established businesses and firms entering biopharma.

That work gives you quantitative and qualitative analyses with independent predictions. You receive information found only in our investigation.

There you find business intelligence to help you understand the future of the biologicals industry and market. You see where prospects are lucrative, where growth is likely.

With our report you are less likely to fall behind in knowledge. Discover how our work could benefit your research and analyses, saving you time too.

Table of Contents

1. Executive Summary

  • 1.1 Leading Biological Drug Manufacturers: Overview of Findings
  • 1.2 Chapter Breakdown
  • 1.3 Research and Analysis Methods
  • 1.4 Scope of this Report
    • 1.4.1 Drugs Considered for this Report

2. Overview of the World Biologicals Market, 2012-2022

  • 2.1 Biological Drugs
    • 2.1.1 Defining the Field
  • 2.2 The Biological Drugs Market, 2011
  • 2.3 Leading Classes of Biological Drug
    • 2.3.1 Therapeutic Proteins
    • 2.3.2 Monoclonal Antibodies (MAbs)
    • 2.3.3 Vaccines
    • 2.3.4 Fusion Proteins
    • 2.3.5 Other Biological Drugs
  • 2.4 The Biological Drugs Market: Overall Revenue Forecast, 2012-2022
  • 2.5. The Biological Drugs Market: Drivers and Restraints, 2012
  • 2.6 Leading 20 Biological Drug Manufacturers, 2011

3. The Leading Biologics Manufacturer: Roche, 2012-2022

  • 3.1 Roche Biologics in 2012: Overview
  • 3.2 Roche Biologics Portfolio, 2012
    • 3.2.1 Rituxan (rituximab)
    • 3.2.2 Avastin (bevacizumab)
    • 3.2.3 Herceptin (trastuzumab)
    • 3.2.4 Lucentis (ranibizumab)
    • 3.2.5 Pegasys (pegylated interferon alpha 2a)
    • 3.2.6 Other Roche Biologics
  • 3.3 Roche Biologics Pipeline, 2012
    • 3.3.1 Obinituzumab (RG7159, GA101)
    • 3.3.2 Onartuzumab (MetMAb, RG3638)
    • 3.3.3 Trastuzumab emtansine (T-DM1, RG3502)
    • 3.3.4 Ocrelizumab (RG1594)
    • 3.3.5 Lebrikizumab
    • 3.3.6 Gantenerumab (RG1450)
  • 3.4 Drivers and Restraints for Roche Biologics, 2012
  • 3.5 Roche Biologics Revenue Forecast, 2012-2022

4. Biotechs and Specialist Manufacturers, 2012-2022

  • 4.1 Amgen, 2012
    • 4.1.1 Amgen Biologics in 2012: Overview
    • 4.1.2 Amgen Biologics Portfolio, 2012
      • 4.1.2.1 Enbrel (etanercept)
      • 4.1.2.2 Neulasta/Neupogen (pegfilgrastim/filgrastim)
      • 4.1.2.3 Epogen (epoetin alpha)/ Aranesp (darbepoietin alpha)
      • 4.1.2.4 Other Amgen Biologics
    • 4.1.3 Amgen's Biologics Pipeline, 2012
      • 4.1.3.1 AMG386
      • 4.1.3.2 Ganitumab (AMG 479)
      • 4.1.3.3 Talimogene Laherparepvec
      • 4.1.3.4 AMG145
      • 4.1.3.5 AMG785
    • 4.1.4 Amgen Drivers and Restraints, 2012
    • 4.1.5 Amgen Biologics Revenue Forecast, 2012-2022
  • 4.2 Biogen Idec, 2012
    • 4.2.1 Biogen Idec Biologics in 2012: Overview
    • 4.2.2 Biogen Idec's Product Portfolio, 2012
      • 4.2.2.1 Avonex (beta-interferon 1a)
      • 4.2.2.2 Tysabri (natalizumab)
    • 4.2.3 Biogen Idec's Biologics Pipeline, 2012
      • 4.2.3.1 PEG-interferon beta-1a (BIIB 017)
      • 4.2.3.2 Recombinant Factor VIII-Fc and Factor IX-Fc
      • 4.2.3.3 Galiximab
    • 4.2.4 Biogen Idec Drivers and Restraints, 2012
    • 4.2.5 Biogen Idec Biologics Revenue Forecast, 2012-2022
  • 4.3 CSL Behring, 2012
    • 4.3.1 CSL Behring Biologics in 2012: Overview
    • 4.3.2 CSL's Product Portfolio, 2012
      • 4.3.2.1 Immunoglobulins
      • 4.3.2.2 Plasma-Derived Coagulants
      • 4.3.2.3 Helixate
      • 4.3.2.4 Albumin
    • 4.3.3 CSL's Biologics Pipeline, 2012
      • 4.3.3.1 Overview of New Products
    • 4.3.4 Drivers and Restraints for CSL
    • 4.3.5 CSL Biologics Revenue Forecast, 2012-2022
  • 4.4 Grifols, 2012
    • 4.4.1 Grifols Biologics in 2012: Overview
    • 4.4.2 Grifols' Product Portfolio, 2012
      • 4.4.2.1 Gamunex/Gamunex-C (Immune Globulin Injection, 10% Caprylate/Chromatography Purified)
      • 4.4.2.2 Prolastin/ Prolastin-C (Alpha-1 Proteinase Inhibitor)
      • 4.4.2.3 Fraction VIII (Koate DVI)
    • 4.4.3 Grifols' Biologics Pipeline, 2012
      • 4.4.3.1 Plasma-Derived and Recombinant Plasmins
    • 4.4.4 Drivers and Restraints for Grifols Biologics, 2012
    • 4.4.5 Market Forecast for Grifols Biologics, 2012-2022
  • 4.5 Allergan, 2012
    • 4.5.1 Allergan Biologics: Overview, 2012
    • 4.5.2 Allergan Product Portfolio, 2012
    • 4.5.3 Allergan Biologics Pipeline: Overview, 2012
    • 4.5.4 Drivers and Restraints for Allergan Biologics, 2012
    • 4.5.5 Market Forecast for Allergan Biologics, 2012-2022

5. Leading Vaccines Manufacturers, 2012-2022

  • 5.1 Sanofi, 2012
    • 5.1.1 Sanofi Biologics: Overview, 2012
    • 5.1.2 Sanofi Biologics Portfolio, 2012
      • 5.1.2.1 Lantus (insulin glargine)
      • 5.1.2.2 Genzyme Legacy Products
      • 5.1.2.3 Polio/Pertussis/Hib Vaccines
      • 5.1.2.4 Influenza Vaccines
      • 5.1.2.5 Other Sanofi Biologics
    • 5.1.3 Sanofi Biologics Pipeline, 2012
      • 5.1.3.1 Hexaxim (DTP-HepB-Polio-Hib Vaccine)
      • 5.1.3.2 Dengue Fever Vaccine
      • 5.1.3.3 Zaltrap (aflibercept)
      • 5.1.3.4 Sarilumab
    • 5.1.4 Drivers and Restraints for Sanofi Biologics, 2012
    • 5.1.5 Market Forecast for Sanofi Biologics, 2012-2022
  • 5.2 Pfizer, 2012
    • 5.2.1 Pfizer Biologics: Overview, 2012
    • 5.2.2 Pfizer Biologics Portfolio, 2012
      • 5.2.2.1 Prevnar-13/Prevnar-7 (Pneumococcal 13-Valent/ 7-Valent Conjugate Vaccine)
    • 5.2.3 Pfizer Biologics Pipeline, 2012
      • 5.2.3.1 Inotuzumab Ozogamicin
      • 5.2.3.2 Fezakinumab
      • 5.2.3.3 Ozoralizumab
      • 5.2.3.4 Tanezumab (RN624)
    • 5.2.4 Drivers and Restraints for Pfizer Biologics
    • 5.2.5 Market Forecast for Pfizer Biologics, 2012-2022
  • 5.3 GlaxoSmithKline, 2012
    • 5.3.1 GlaxoSmithKline Biologics: Overview, 2012
    • 5.3.2 GlaxoSmithKline Biologics Portfolio, 2012
      • 5.3.2.1 Infanrix/Pediarix
      • 5.3.2.2 Hepatitis Vaccines
      • 5.3.2.3 Cervarix
      • 5.3.2.4 Synflorix
      • 5.3.2.5 Other GlaxoSmithKline Biologics, 2012
    • 5.3.3 GlaxoSmithKline Biologics Pipeline, 2012
      • 5.3.3.1 Astuprotimut (MAGE-A3 Therapeutic Vaccine)
      • 5.3.3.2 Menhibrix (Meningitis C and Y and Hib Vaccine)
      • 5.3.3.3 GSK1437173A (Varicella Zoster Virus Vaccine)
      • 5.3.3.4 Mosquirix
      • 5.3.3.5 Nimenrix
    • 5.3.4 Drivers and Restraints for GlaxoSmithKline Biologics, 2012
    • 5.3.5 Market Forecast for GlaxoSmithKline, 2012-2022
  • 5.4 Merck & Co., 2012
    • 5.4.1 Merck Biologics: Overview, 2012
    • 5.4.2 Merck Biologics Portfolio: Overview, 2012
      • 5.4.2.1 Gardasil
      • 5.4.2.2 ProQuad/ MMR-II/ Varivax
      • 5.4.2.3 PegIntron (peginterferon alpha-2b)
      • 5.4.2.4 RotaTeq
      • 5.4.2.5 Other Merck Biologics, 2012
    • 5.4.3 Merck Biologics Pipeline, 2012
      • 5.4.3.1 V503
      • 5.4.3.2 V212
      • 5.4.3.3 Allergy Vaccines
      • 5.4.3.4 MK-0646
    • 5.4.4 Drivers and Restraints for Merck Biologics, 2012
    • 5.4.5 Market Forecast for Merck Biologics, 2012-2022
  • 5.5 Novartis, 2012
    • 5.5.1 Novartis Biologics: Overview, 2012
    • 5.5.2 Novartis Biologics Portfolio, 2012
      • 5.5.2.1 Novartis Vaccines
    • 5.5.3 Novartis Biologics Pipeline, 2012
      • 5.5.3.1 Bexsero
    • 5.5.4 Drivers and Restraints for Novartis Biologics, 2012
    • 5.5.5 Market Forecast for Novartis Biologics, 2012-2022

6. Leading European Biologics Manufacturers, 2012-2022

  • 6.1 Novo Nordisk, 2012
    • 6.1.1 Novo Nordisk Biologics: Overview, 2012
    • 6.1.2 Novo Nordisk's Biologics Portfolio, 2012
      • 6.1.2.1 NovoRapid/ NovoLog (insulin aspart)
      • 6.1.2.2 NovoSeven (eptacog alpha)
      • 6.1.2.3 Levemir (insulin detemir)
      • 6.1.2.4 Norditropin (Somatropin Injection)
    • 6.1.3 Novo Nordisk's Biologics Pipeline, 2012
      • 6.1.3.1 Tresiba (Insulin Degludec)
      • 6.1.3.2 Catridecacog
      • 6.1.3.3 NN7008
    • 6.1.4 Drivers and Restraints for Novo Nordisk
    • 6.1.5 Market Forecast for Novo Nordisk Biologics, 2012-2022
  • 6.2 Merck KGaA
    • 6.2.1 Merck KGaA Biologics: Overview
    • 6.2.2 Merck KGaA Portfolio, 2012
      • 6.2.2.1 Rebif (interferon beta-1a)
      • 6.2.2.2 Erbitux (cetuximab)
    • 6.2.3 Merck KGaA Pipeline, 2012
      • 6.2.3.1 Atacicept (TACI-Ig)
      • 6.2.3.2 Adecatumumab
      • 6.2.3.3 Stimuvax (emepepimut-S)
      • 6.2.3.4 SEED Bodies
    • 6.2.4 Drivers and Restraints for Merck KGaA
    • 6.2.5. Market Forecast for Merck KGaA
  • 6.3 Bayer
    • 6.3.1 Bayer Biologics: Overview, 2012
    • 6.3.2 Bayer Biologics Portfolio, 2012
      • 6.3.2.1 Betaferon (interferon beta-1b)
      • 6.3.2.2 Kogenate (recombinant Factor VIII)
      • 6.3.2.3 Eylea (aflibercept)
    • 6.3.3 Bayer Pipeline, 2012
      • 6.3.3.1 L19-131I
      • 6.3.3.2 L19-TNF
      • 6.3.3.3 BAY 94-9027
    • 6.3.4 Drivers and Restraints for Bayer Biologics, 2012
    • 6.3.5 Market Forecast for Bayer Biologics, 2012-2022
  • 6.4 AstraZeneca
    • 6.4.1 AstraZeneca Biologics Overview, 2012
    • 6.4.2 AstraZeneca Biologics Portfolio, 2012
      • 6.4.2.1 Synagis (palivizumab)
    • 6.4.3 AstraZeneca Biologics Pipeline, 2012
    • 6.4.4 AstraZeneca Biologics Drivers and Restraints, 2012
    • 6.4.5 AstraZeneca Market Forecast, 2012-2022

7. Leading US Biologics Manufacturers, 2012-2022

  • 7.1 Johnson & Johnson
    • 7.1.1 Johnson & Johnson Biologics: Overview, 2012
    • 7.1.2 Johnson & Johnson Biologics Portfolio
      • 7.1.2.1 Remicade (infliximab)
      • 7.1.2.2 Stelara (ustekinumab)
      • 7.1.2.3 Other Johnson & Johnson Biologics
    • 7.1.3 Johnson & Johnson Biologics Pipeline
      • 7.1.3.1 Bapineuzumab
      • 7.1.3.2 Fulranumab
      • 7.1.3.3 CNTO 328 (siltuximab)
    • 7.1.4 Johnson & Johnson Biologics Drivers and Restraints, 2012
    • 7.1.5 Johnson & Johnson Market Forecast, 2012-2022
  • 7.2 Abbott Laboratories
    • 7.2.1 Abbott Laboratories Biologics: Overview, 2012
    • 7.2.2 Abbott Laboratories Biologics Portfolio, 2012
      • 7.2.2.1 Humira (adalimumab)
    • 7.2.3 Abbott Laboratories Biologics Pipeline, 2012
      • 7.2.3.1 Daclizumab
    • 7.2.4 Abbott Laboratories Biologics Drivers and Restraints, 2012
    • 7.2.5 Abbott Laboratories Biologics Market Forecast, 2012-2022
  • 7.3 Baxter
    • 7.3.1 Baxter Biologics: Overview, 2012
    • 7.3.2 Baxter Biologics Portfolio, 2012
      • 7.3.2.1 Recombinants
      • 7.3.2.2 Other Areas
    • 7.3.3 Baxter Biologics Pipeline, 2012
      • 7.3.3.1 BAX111 (Recombinant von Willebrand Factor)
      • 7.3.3.2 Adult Autologous Stem Cell Therapy
      • 7.3.3.3 KUR-211 (Growth Factor)
    • 7.3.4 Baxter Biologics Drivers and Restraints, 2012
    • 7.3.5 Baxter Biologics Market Forecast, 2012-2022
  • 7.4 Eli Lilly, 2012
    • 7.4.1 Eli Lilly Biologics: Overview, 2012
    • 7.4.2 Eli Lilly Biologics Portfolio, 2012
      • 7.4.2.1 Humalog(insulin lispro)
      • 7.4.2.2 Humulin
    • 7.4.3 Eli Lilly Biologics Pipeline, 2012
      • 7.4.3.1 Liprotamase (Enzyme Replacement Therapy)
      • 7.4.3.2 Solanezumab
      • 7.4.3.3 Necitumumab
      • 7.4.3.4 Ramicirumab
      • 7.4.3.5 GLP1 FC Fusion Protein
      • 7.4.3.6 Tabalumab
    • 7.4.4 Eli Lilly Biologics Drivers and Restraints, 2012
    • 7.4.5 Eli Lilly Biologics Market Forecast, 2012-2022
  • 7.5 Bristol-Myers Squibb, 2012
    • 7.5.1 Bristol-Myers Squibb Biologics: Overview, 2012
    • 7.5.2 Bristol-Myers Squibb Biologics Portfolio, 2012
      • 7.5.2.1 Orencia (abatacept)
      • 7.5.2.2 Other Bristol-Myers Squibb Biologics
    • 7.5.3 Bristol-Myers Squibb Biologics Pipeline, 2012
      • 7.5.3.1 Elotuzumab
      • 7.5.3.2 Anti-PD1 MAb (BMS-936558)
    • 7.5.4 Bristol-Myers Squibb Biologics Drivers and Restraints, 2012
    • 7.5.5 Bristol-Myers Squibb Biologics Market Forecast, 2012-2022

List of Tables

  • Table 1.1 Currency Exchange Rates, 2011
  • Table 2.2 Biological Drugs Market by Class, Revenues ($bn), Market Share (%), 2011
  • Table 2.3 Therapeutic Proteins: Role in the Biological Drugs Market, 2011
  • Table 2.4 MAbs: Role in the Biological Drugs Market, 2011
  • Table 2.5 Vaccines: Role in the Biological Drugs Market, 2011
  • Table 2.6 Fusion Proteins: Role in the Biological Drugs Market, 2011
  • Table 2.7 Other Biologics: Role in the Biological Drugs Market, 2011
  • Table 2.8 Biological Drugs Market by Class: Revenues ($bn), Market Share (%), CAGR (%), 2011, 2016, 2022
  • Table 2.9 Top 20 Biological Manufacturers: Revenue ($bn), Market Share (%), 2011
  • Table 3.1 Roche: Key Facts, 2012
  • Table 3.2 Roche: Leading Biologics, Revenues ($bn), Share of Biologics Revenue (%), 2011
  • Table 3.3 Roche: Selected Pipeline Biologics, Phase II and III, 2012
  • Table 3.4 Roche: Selected Pipeline Biologics, Phase I, 2012
  • Table 3.5 Roche Biologics, Market Forecast ($bn, AGR %, CAGR %), 2011-2016
  • Table 3.6 Roche Biologics, Market Forecast ($bn, AGR %, CAGR %), 2017-2022
  • Table 4.1 Amgen: Key Facts, 2012
  • Table 4.2 Amgen: Key M&A Deals, 2012
  • Table 4.3 Amgen: Lead Biologics Revenues ($bn), Share of Biologics Revenue (%), 2011
  • Table 4.4 Amgen: Selected Pipeline Biologics, 2012
  • Table 4.5 Amgen: Market Forecast ($bn, AGR %, CAGR %), 2011-2016
  • Table 4.6 Amgen: Market Forecast ($bn, AGR %, CAGR %), 2017-2022
  • Table 4.7 Biogen Idec: Key Facts, 2012
  • Table 4.8 Biogen Idec: Ongoing Collaborations, 2012
  • Table 4.9 Biogen Idec: Lead Biologics Revenues ($bn), Share of Biologics Revenue (%), 2011
  • Table 4.10 Biogen Idec: Selected Pipeline Biologics, 2012
  • Table 4.11 Biogen Idec: Market Forecast ($bn, AGR %, CAGR %), 2011-2016
  • Table 4.12 Biogen Idec: Market Forecast ($bn, AGR %, CAGR %), 2017-2022
  • Table 4.13 CSL Behring: Key Facts, 2012
  • Table 4.14 CSL: Shares of Company's Biologics Revenue (%), 2011
  • Table 4.15 CSL: Selected Pipeline Biologics, 2012
  • Table 4.16 CSL: Market Forecast ($bn, AGR %, CAGR %), 2011-2016
  • Table 4.17 CSL: Market Forecast ($bn, AGR %, CAGR %), 2017-2022
  • Table 4.18 Grifols: Key Facts, 2012
  • Table 4.19 Grifols: Selected Biologics, Revenues ($bn), 2010
  • Table 4.20 Grifols: Market Forecast ($bn, AGR %, CAGR %), 2011-2016
  • Table 4.21 Grifols: Market Forecast ($bn, AGR %, CAGR %), 2017-2022
  • Table 4.22 Allergan: Key Facts, 2012
  • Table 4.23 FDA-Approved On-Label Uses of Botox with Approval Date, 2012
  • Table 4.24 Allergan: Market Forecast ($bn, AGR %, CAGR %), 2011-2016
  • Table 4.25 Allergan: Market Forecast ($bn, AGR %, CAGR %), 2017-2022
  • Table 5.1 Sanofi: Key Facts, 2012
  • Table 5.2 Sanofi: Leading Biologics, Revenues ($bn), Share of Revenues (%), 2011
  • Table 5.3 Sanofi: Selected Phase III Pipeline Biologics, 2012
  • Table 5.4 Sanofi: Selected Phase I and Phase II Pipeline Biologics, 2012
  • Table 5.5 Sanofi: Market Forecast ($bn, AGR %, CAGR %), 2011-2016
  • Table 5.6 Sanofi: Market Forecast ($bn, AGR %, CAGR %), 2017-2022
  • Table 5.7 Pfizer: Key Facts, 2012
  • Table 5.8 Pfizer: Leading Biologics, Revenues ($bn), Share of Revenues (%), 2011
  • Table 5.9 Pfizer: Selected Phase III and Phase II Pipeline, 2012
  • Table 5.10 Pfizer: Selected Early-Stage Pipeline, 2012
  • Table 5.11 Pfizer: Market Forecast ($bn, AGR %, CAGR %), 2011-2016
  • Table 5.12 Pfizer: Market Forecast ($bn, AGR %, CAGR %), 2017-2022
  • Table 5.13 GlaxoSmithKline: Key Facts, 2012
  • Table 5.14 GlaxoSmithKline: Leading Biologics, Revenues ($bn), Share of Revenues (%), 2011
  • Table 5.15 GlaxoSmithKline: Selected Late-Stage Pipeline, 2012
  • Table 5.16 GlaxoSmithKline: Selected Phase I and Phase II Pipeline, 2012
  • Table 5.17 GlaxoSmithKline: Market Forecast ($bn, AGR %, CAGR %), 2011-2016
  • Table 5.18 GlaxoSmithKline: Market Forecast ($bn, AGR %, CAGR %), 2017-2022
  • Table 5.19 Merck: Key Facts, 2012
  • Table 5.20 Leading Biologics, Revenues ($bn), Share of Revenues (%), 2011
  • Table 5.21 Merck: Selected Pipeline Biologics, 2012
  • Table 5.22 Merck: Market Forecast ($bn, AGR %, CAGR %), 2011-2016
  • Table 5.23 Merck: Market Forecast ($bn, AGR %, CAGR %), 2017-2022
  • Table 5.24 Novartis: Key Facts, 2012
  • Table 5.25 Leading Novartis Biologics, Revenues ($bn), Share of Revenues (%), 2011
  • Table 5.26 Novartis: Selected Pipeline Biologics, 2012
  • Table 5.27 Novartis: Market Forecast ($bn, AGR %, CAGR %), 2011-2016
  • Table 5.28 Novartis: Market Forecast ($bn, AGR %, CAGR %), 2017-2022
  • Table 6.1 Novo Nordisk: Key Facts, 2012
  • Table 6.2 Novo Nordisk Leading Biologics, Revenues ($bn), Share of Revenues (%), 2011
  • Table 6.3 Novo Nordisk: Selected Pipeline Biologics, 2012
  • Table 6.4 Novo Nordisk Biologics, Market Forecast ($bn, AGR %, CAGR %), 2011-2016
  • Table 6.5 Novo Nordisk Biologics, Market Forecast ($bn, AGR %, CAGR %), 2017-2022
  • Table 6.6 Merck KGaA: Key Facts, 2012
  • Table 6.7 Merck KGaA Leading Biologics, Revenues ($bn), Share of Revenues (%), 2011
  • Table 6.8 Merck KGaA Selected Pipeline, 2012
  • Table 6.9 Merck KGaA Biologics, Market Forecast ($bn, AGR %, CAGR %), 2011-2016
  • Table 6.10 Merck KGaA Biologics, Market Forecast ($bn, AGR %, CAGR %), 2017-2022
  • Table 6.11 Bayer: Key Facts, 2012
  • Table 6.12 Bayer Leading Biologics, Revenues ($bn), Share of Revenues (%), 2011
  • Table 6.13 Bayer Selected Pipeline, 2012
  • Table 6.14 Bayer Biologics, Market Forecast ($bn, AGR %, CAGR %), 2011-2016
  • Table 6.15 Bayer Biologics, Market Forecast ($bn, AGR %, CAGR %), 2017-2022
  • Table 6.16 AstraZeneca: Key Facts, 2012
  • Table 6.17 AstraZeneca: Leading Biologics, Revenues ($bn), Share of Total Revenues (%), 2011
  • Table 6.18 AstraZeneca: Selected Biologics Pipeline, 2012
  • Table 6.19 AstraZeneca Biologics, Market Forecast ($bn, AGR %, CAGR %), 2011-2016
  • Table 6.20 AstraZeneca Biologics, Market Forecast ($bn, AGR %, CAGR %), 2017-2022
  • Table 7.1 Johnson & Johnson: Key Facts, 2012
  • Table 7.2 Johnson & Johnson: Leading Biologics, Revenues ($bn), Share of Total Revenues (%), 2011
  • Table 7.3 Johnson & Johnson Selected Pipeline, 2011
  • Table 7.4 Johnson & Johnson Biologics, Market Forecast ($bn, AGR %, CAGR %), 2011-2016
  • Table 7.5 Johnson & Johnson Biologics, Market Forecast ($bn, AGR %, CAGR %), 2017-2022
  • Table 7.6 Abbott Laboratories: Key Facts, 2012
  • Table 7.7 Abbott: Leading Biologics, Revenues ($bn), Share of Total Revenues (%), 2011
  • Table 7.8 Abbott: Selected Pipeline, 2012
  • Table 7.9 Abbott Laboratories Biologics, Market Forecast ($bn, AGR %, CAGR %), 2011-2016
  • Table 7.10 Abbott Laboratories Biologics, Market Forecast ($bn, AGR %, CAGR %), 2017-2022
  • Table 7.11 Baxter: Key Facts, 2012
  • Table 7.12 Baxter: Leading Biologics, Revenues ($bn), Share of Total Revenues (%), 2011
  • Table 7.13 Baxter: Selected Pipeline, 2012
  • Table 7.14 Baxter Biologics, Market Forecast ($bn, AGR %, CAGR %), 2011-2016
  • Table 7.15 Baxter Biologics, Market Forecast ($bn, AGR %, CAGR %), 2017-2022
  • Table 7.16 Eli Lilly: Key Facts, 2012
  • Table 7.17 Eli Lilly: Leading Biologics, Revenues ($bn), Share of Total Revenues (%), 2011
  • Table 7.18 Eli Lilly: Selected Biologics Pipeline, 2012
  • Table 7.19 Eli Lilly Biologics, Market Forecast ($bn, AGR %, CAGR %), 2011-2016
  • Table 7.20 Eli Lilly Biologics, Market Forecast ($bn, AGR %, CAGR %), 2017-2022
  • Table 7.21 Bristol-Myers Squibb: Key Facts, 2012
  • Table 7.22 Bristol-Myers Squibb: Leading Biologics, Revenues ($bn), Share of Total Revenues (%), 2011
  • Table 7.23 Bristol-Myers Squibb: Selected Biologics Pipeline, 2012
  • Table 7.24 Bristol-Myers Squibb Biologics, Market Forecast ($bn, AGR %, CAGR %), 2011-2016
  • Table 7.25 Bristol-Myers Squibb Biologics, Market Forecast ($bn, AGR %, CAGR %), 2017-2022

List of Figures

  • Figure 2.1 Biological Drugs Market by Class, Market Share (%), 2011
  • Figure 2.2 Biological Drugs Market by Class: Revenues ($bn), 2011, 2016, 2022
  • Figure 2.3 Biological Drugs Market: Drivers and Restraints, 2012-2022
  • Figure 2.4 Top 20 Biological Manufacturers: Market Share (%), 2011
  • Figure 3.1 Regional Distribution of Roche Sales (%), 2011
  • Figure 3.2 Roche: Leading Biologics, Share of Total Revenues (%), 2011
  • Figure 3.3 Drivers and Restraints for Roche Biologics, 2012
  • Figure 3.4 Roche: Market Forecast ($bn), 2011-2022
  • Figure 4.1 Amgen: Lead Biologics Share of Overall Revenues (%), 2011
  • Figure 4.2 Drivers and Restraints for Amgen Biologics, 2012
  • Figure 4.3 Amgen: Market Forecast ($bn), 2011-2022
  • Figure 4.4 Biogen Idec: Lead Biologics Share of Overall Revenues (%), 2011
  • Figure 4.5 Biogen Idec: Drivers and Restraints, 2012
  • Figure 4.6 Biogen Idec: Market Forecast ($bn), 2011-2022
  • Figure 4.7 CSL Behring: Regional Breakdown of Revenues (%), 2011
  • Figure 4.8 CSL Behring: Lead Biologics Share of Revenues (%), 2011.
  • Figure 4.9 Drivers and Restraints for CSL Biologics, 2012
  • Figure 4.10 CSL Behring: Market Forecast ($bn), 2011-2022
  • Figure 4.11 Grifols: Breakdown of Revenues by Business Segment (%), 2011
  • Figure 4.12 Grifols: Regional Distribution of Revenues (%), 2009-2011
  • Figure 4.13 Grifols: Selected Biologics ($bn), 2010
  • Figure 4.14 Drivers and Restraints for Grifols Biologics, 2012
  • Figure 4.15 Grifols: Market Forecast ($bn), 2011-2022
  • Figure 4.16 Allergan: Breakdown of Pharmaceutical Revenues (%), 2011
  • Figure 4.17 Allergan: Geographical Breakdown of Revenues (%), 2011
  • Figure 4.18 Drivers and Restraints for Allergan Biologics, 2012
  • Figure 4.19 Allergan: Market Forecast ($bn), 2011-2022
  • Figure 5.1 Sanofi: Revenue Breakdown by Business Segment (%), 2011
  • Figure 5.2 Sanofi: Leading Biologics, Share of Revenues (%), 2011
  • Figure 5.3 Drivers and Restraints for Sanofi Biologics, 2012
  • Figure 5.4 Sanofi: Market Forecast ($bn), 2011-2022
  • Figure 5.5 Pfizer: Leading Biologics, Share of Revenues (%), 2011
  • Figure 5.6 Drivers and Restraints for Pfizer Biologics, 2012
  • Figure 5.7 Pfizer: Market Forecast ($bn), 2011-2022
  • Figure 5.8 GlaxoSmithKline: Business Breakdown by Segment (%), 2011
  • Figure 5.9 Drivers and Restraints for GlaxoSmithKline Biologics, 2012
  • Figure 5.10 GlaxoSmithKline: Market Forecast ($bn), 2011-2022
  • Figure 5.11 Leading Biologics, Share of Revenues (%), 2011
  • Figure 5.12 Drivers and Restraints for Merck Biologics, 2012
  • Figure 5.13 Merck: Market Forecast ($bn), 2011-2022
  • Figure 5.14 Leading Novartis Biologics, Share of Revenues (%), 2011
  • Figure 5.15 Drivers and Restraints for Novartis Biologics, 2012
  • Figure 5.16 Novartis: Market Forecast ($bn), 2011-2022
  • Figure 6.1 Novo Nordisk: Revenue Breakdown (%) by Business Segment, 2012
  • Figure 6.2 Novo Nordisk Leading Biologics, Share of Revenues (%), 2011
  • Figure 6.3 Drivers and Restraints for Novo Nordisk Biologics, 2012
  • Figure 6.4 Novo Nordisk Market Forecast ($bn), 2011-2022
  • Figure 6.5 Merck KGaA Leading Biologics, Share of Revenues (%), 2011
  • Figure 6.6 Drivers and Restraints for Merck KGaA, 2012
  • Figure 6.7 Merck KGaA Biologics, Market Forecast ($bn), 2011-2022
  • Figure 6.8 Bayer: Distribution of Revenues by Business (%), 2011
  • Figure 6.9 Bayer: Distribution of Revenues by Region (%), 2011
  • Figure 6.10 Bayer Leading Biologics, Share of Revenues (%), 2011
  • Figure 6.11 Drivers and Restraints for Bayer Biologics, 2012
  • Figure 6.12 Bayer Biologics, Market Forecast ($bn), 2011-2022
  • Figure 6.13 AstraZeneca: Regional Distribution of Revenues (%), 2011
  • Figure 6.14 AstraZeneca: Leading Biologics, Share of Total Revenues (%), 2011
  • Figure 6.15 Drivers and Restraints for AstraZeneca Biologics, 2012
  • Figure 6.16 AstraZeneca Biologics, Market Forecast ($bn), 2011-2022
  • Figure 7.1 Johnson & Johnson: Revenues Breakdown by Business Segment (%), 2012
  • Figure 7.2 Johnson & Johnson: Leading Biologics, Share of Total Revenues (%), 2011
  • Figure 7.3 Drivers and Restraints for Johnson & Johnson Biologics, 2012
  • Figure 7.4 Johnson & Johnson Biologics, Market Forecast ($bn), 2011-2022
  • Figure 7.5 Abbott Laboratories: Revenue Breakdown by Business Segment (%), 2012
  • Figure 7.6 Abbott: Leading Biologics, Share of Total Revenues (%), 2011
  • Figure 7.7 Drivers and Restraints for Abbott, 2012
  • Figure 7.8 Abbott Laboratories Biologics, Market Forecast ($bn), 2011-2022
  • Figure 7.9 Baxter: Breakdown of Revenues by Business (%), 2011
  • Figure 7.10 Baxter: Breakdown of Revenues by Region (%), 2011
  • Figure 7.11 Baxter: Share of Total Revenues (%), 2011
  • Figure 7.12 Drivers and Restraints for Baxter Biologics, 2012
  • Figure 7.13 Baxter Biologics, Market Forecast ($bn), 2011-2022
  • Figure 7.14 Eli Lilly: Breakdown of Pharmaceutical Sales by Therapeutic Area (%), 2011
  • Figure 7.15 Eli Lilly: Leading Biologics, Share of Total Revenues (%), 2011
  • Figure 7.16 Drivers and Restraints for Eli Lilly Biologics, 2012
  • Figure 7.17 Eli Lilly Biologics, Market Forecast ($bn), 2011-2022
  • Figure 7.18 Bristol-Myers Squibb: Regional Distribution of Revenues (%), 2011
  • Figure 7.19 Bristol-Myers Squibb: Leading Biologics, Share of Total Revenues (%), 2011
  • Figure 7.20 Drivers and Restraints for Bristol-Myers Squibb Biologics, 2012
  • Figure 7.21 Bristol-Myers Squibb Biologics, Market Forecast ($bn), 2011-2022

Companies Listed

  • Abbott Laboratories
  • Abgenix
  • Ablynx
  • AC Immune
  • Acadia Pharmaceuticals
  • Acorda Therapeutics
  • Alantos Pharmaceuticals
  • ALK Abello
  • Allergan
  • Alnara Pharmaceuticals
  • Amgen
  • AstraZeneca
  • Avidia
  • Baxter International
  • Bayer HealthCare
  • Becton Dickinson
  • Biogen Idec
  • Bioheart
  • Biomira
  • BioVex
  • Boehringer Ingelheim
  • Bristol-Myers Squibb (BMS)
  • Cambridge Antibody Technologies
  • Centocor Ortho Biotech
  • Chinese Academy of Medical Sciences
  • Chinese Academy of Sciences
  • Chiron
  • Cilag Chemie
  • Coley Pharmaceuticals
  • Corixa
  • Cougar Biotechnology
  • CovX
  • Crucell Biotechnology
  • CSL Behring
  • CSL Biotherapies
  • CT Arztneimittel
  • Cytori
  • Dompe
  • Duke University
  • Dyax
  • Dynavax
  • Eisai
  • Elan
  • Eli Lilly
  • EMD Serono
  • Encysive Pharmaceuticals
  • ExonHit Therapeutics
  • Facet Biotech
  • Fresenius
  • F-Star
  • Galena Biopharma
  • Genentech
  • Genesis Pharma
  • Genetics Institute
  • Genmab
  • Genzyme
  • GlaxoSmithKline
  • GlycoFi
  • Grifols
  • GTC Biotherapeutics
  • HD Biosciences
  • Hexal
  • Hoechst Marion Roussel
  • Hospira
  • HudsonAlpha Institute for Biotechnology
  • Human Genome Sciences
  • Hutchison MediPharma
  • ID Biomedical
  • Ilypsa
  • ImClone
  • Immunex Corporation
  • ImmunoGen
  • Inspire Pharmaceuticals
  • Institute for Genomic Research
  • International Vaccine Institute
  • Ipsen
  • Janssen Pharmaceutica
  • Jiangsu Walvax Biotech Company
  • Johns Hopkins University
  • Johnson & Johnson
  • KAI Pharmaceuticals
  • Kinetix Pharmaceuticals
  • King
  • Knopp Neurosciences
  • Kuros
  • Kyorin Pharmaceutical
  • Kyowa Hakko Kirin
  • Lipoxen
  • Ludwig Institute for Cancer Research
  • McNeil Laboratories
  • Medarex
  • MedImmune
  • Medixion
  • Megapharm
  • Merck & Co.
  • Merck BioVentures
  • Merck KGaA
  • Merck-Banyu
  • Merz Pharma
  • Micromet
  • Millipore
  • Mitsubishi Tanabe Pharma
  • Molecular Partners
  • MorphoSys
  • Mustafa Nevzat Pharmaceuticals
  • National Center for Drug Screening (China)
  • Nestle
  • Neurimmune SubOne
  • Novartis
  • Novo Nordisk
  • Oncothyreon
  • Ortho Pharmaceutical
  • Oxford University
  • Pasteur Merieux Serums & Vaccins
  • PDL BioPharma
  • Peptech
  • Pfizer
  • Pharmacia
  • Philogen
  • Pieris
  • Piramal
  • Portola Pharmaceuticals
  • PowderMed
  • Protein Design
  • Regeneron
  • Roche
  • Sabin Vaccine Institute
  • Samsung Biologics
  • Sandoz
  • Sanofi
  • Sanofi Pasteur MSD
  • Sanwa Kagaku Kenkyusho
  • Schering-Plough
  • Senju Pharmaceutical
  • Serenex
  • Shanghai ChemExplorer
  • Shanghai Institute of Biological Sciences
  • Shanghai Institute of Materia Medica
  • Shantha Biotechnics
  • Sirna Therapeutics
  • Solvay Pharmaceuticals
  • Swedish Orphan Biovitrum
  • Synergen
  • Synovis Life Technologies
  • Syntonix
  • Takeda
  • Talecris
  • Teva Pharmaceutical Industries
  • Tianjin Medical University Cancer Hospital
  • Transkaryotic Therapies
  • Trellis Bioscience
  • Trubion
  • Tularik
  • University of Queensland
  • Upjohn
  • Vaxdesign
  • Vernalis
  • VIVALis
  • Walter Reed Army Institute
  • Warner-Lambert
  • World Health Organization (WHO)
  • WuXi AppTec
  • Wyeth Pharmaceuticals
  • Zhejiang Taiyuan
  • Zydus Cadila
  • ZymoGenetics
Back to Top